Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Treasury Shares (2016 - 2026)

Intellia Therapeutics has reported Treasury Shares over the past 12 years, most recently at $6.3 million for Q1 2026.

  • Quarterly Treasury Shares rose 13.83% to $6.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $6.3 million through Mar 2026, up 13.83% year-over-year, with the annual reading at $5.2 million for FY2025, 6.33% down from the prior year.
  • Treasury Shares was $6.3 million for Q1 2026 at Intellia Therapeutics, up from $5.2 million in the prior quarter.
  • Over five years, Treasury Shares peaked at $6.3 million in Q1 2026 and troughed at $1.4 million in Q1 2022.
  • The 5-year median for Treasury Shares is $5.2 million (2025), against an average of $4.3 million.
  • Year-over-year, Treasury Shares soared 334.88% in 2022 and then dropped 6.33% in 2025.
  • A 5-year view of Treasury Shares shows it stood at $1.9 million in 2022, then surged by 108.19% to $4.0 million in 2023, then surged by 37.26% to $5.5 million in 2024, then decreased by 6.33% to $5.2 million in 2025, then increased by 21.05% to $6.3 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Treasury Shares are $6.3 million (Q1 2026), $5.2 million (Q4 2025), and $5.2 million (Q3 2025).